Nicox S.A., an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally.
The last earnings update was 49 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Nicox. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Nicox's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Nicox is high growth as no earnings estimate data is available.
Unable to determine if Nicox is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Nicox's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Michele Garufi co-founded Nicox SA in 1996 and has been its Chief Executive Officer since February 15, 1996. Mr. Garufi is a co-founder of Scharper Ltd. He serves as an Administrator of Scharper SpA. He has an extensive experience in business development, licensing and international marketing in the European pharmaceutical industry. He served as the President at Nicox SA since February 15, 1996. Until March 1996, he served as a Vice President of the Division International and Directing Licenses Activities at Recordati Italy and Managing Director of Recordati's subsidiary in Spain. Mr. Garufi served as Director of the International Division of Italfarmaco from 1988 to 1992, Assistant to the Chief Executive Officer of Polished Chimica from 1984 to 1988, Assistant to the President at Medea Research since 1983 and Technical Director of one of the Italian subsidiaries of the Lipha Group from 1978 to 1982. He co-founded Relivia Srl and serves as its Chairman. He serves as the Chairman of Nicox SA. He served as a Non-Executive Director of Novexel SA. He serves as a member of the Board of Scharper Srl. He serves as a Director of Lica Pharmaceuticals A/S. He served as an Independent Director of Novuspharma SpA. Mr. Garufi graduated with full honors in Pharmaceutical Chemistry from the University of Milan in 1977.
Michele's compensation has increased whilst company is loss making.
Michele's remuneration is higher than average for companies of similar size in Germany.
Vice President of Finance
Michael V. Bergamini
Chief Scientific Advisor
Senior Director of Legal Affairs
Executive VP & Chief Business Officer
Executive VP & Head of Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Nicox board of directors is less than 3 years, this suggests a new board.
Nicox S.A., an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. The company’s product pipeline includes VyzultaTM, an intraocular pressure-lowering treatment; and NCX 470, a nitric oxide (NO)-donating candidate to treat glaucoma, as well as stand-alone NO donors for specific applications in ophthalmic diseases. It also develops ZERVIATE, an eye drop formulation of cetirizine for allergic conjunctivitis; NCX 4280, an ophthalmic solution that targets morning ocular congestion; and NCX 4251, a patented formulation of fluticasone propionate to treat blepharitis. The company has collaborations with Bausch + Lomb, Astra Zeneca, Merck, Pfizer, and Ironwood Pharmaceuticals, Inc., as well as Novaliq GmbH. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.